{"id":275151,"date":"2020-11-12T08:15:39","date_gmt":"2020-11-12T13:15:39","guid":{"rendered":"https:\/\/canadianinquirer.net\/v1\/?p=275151"},"modified":"2020-11-12T08:15:39","modified_gmt":"2020-11-12T13:15:39","slug":"richest-countries-already-bought-80-of-pfizer-vaccine","status":"publish","type":"post","link":"https:\/\/canadianinquirer.net\/v1\/2020\/11\/12\/richest-countries-already-bought-80-of-pfizer-vaccine\/","title":{"rendered":"‘Richest countries already bought 80% of Pfizer vaccine’"},"content":{"rendered":"
\"\"<\/a>
The Global Justice Now analysis shows that more than 1 billion doses have been bought by rich governments, which represent only 14 percent of the global population. (Pixabay photo)<\/figcaption><\/figure>\n

LONDON<\/strong>\u00a0\u2013 More than 80 percent of the US drugmaker Pfizer\u2019s coronavirus disease 2019 (Covid-19) vaccine has already been sold to the richest governments across the world, according to an analysis by a UK-based campaign group.<\/p>\n

The Global Justice Now analysis shows that more than 1 billion doses have been bought by rich governments, which represent only 14 percent of the global population.<\/p>\n

Big purchases include the European Union with 200 million doses and an option for a further 100 million, the United Kingdom with 40 million, and the United States with 100 million and an option to buy another 500 million, according to the group.<\/p>\n

Pfizer\u2019s coronavirus vaccine candidate is more than 90 percent effective in preventing Covid-19, the company announced Monday, raising hopes in fighting the deadly strain.<\/p>\n

The company said it would produce 1.3 billion doses of its vaccine, produced in partnership with the German company BioNTech, by the end of 2021.<\/p>\n

\u201cPfizer is likely to offer some doses to developing countries in the coming weeks through the global COVAX Facility, but these are likely to represent a small fraction of the vaccines produced,\u201d the campaign group said.<\/p>\n

The analysis also suggested that while promoting a fair distribution of vaccines produced, big countries also undermine these schemes by their vast purchase of them.<\/p>\n

\u201cOn the one hand, the British government is helping limit supply of these drugs by insisting on global patent rules that prevent countries producing their own generic vaccines,\u201d said Nick Dearden, director of Global Justice Now.<\/p>\n

On the other, Dearden said, it is buying up as much of that limited supply as it can, so no vaccines are left for developing countries.<\/p>\n

\u201cYou couldn\u2019t get a clearer example of how unequal the pharmaceutical system is \u2013 some make billions of pounds, while many others die because they cannot afford treatments or there are no more left for them to buy. It\u2019s got to change,\u201d he added.<\/p>\n

Dearden also said \u201cunless we break the stranglehold of these massive corporations over our medicines, the injustice will continue.\u201d<\/p>\n

\u201cIt is imperative that we end the vaccine nationalism and that sufficient supply is made available to all, on a fair basis, as a matter of urgency. That can be helped by supporting governments like South Africa and India who are trying to suspend intellectual property rules at the WTO (World Trade Organization) during this global emergency,” he said.\u00a0(Anadolu)<\/strong><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

LONDON\u00a0\u2013 More than 80 percent of the US drugmaker Pfizer\u2019s coronavirus disease 2019 (Covid-19) vaccine has already been sold to …<\/p>\n","protected":false},"author":44,"featured_media":274346,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16,17],"tags":[],"class_list":["post-275151","post","type-post","status-publish","format-standard","has-post-thumbnail","category-news","category-news-w","mauthors-anadolu","mauthors-philippine-news-agency"],"_links":{"self":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/275151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/users\/44"}],"replies":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/comments?post=275151"}],"version-history":[{"count":1,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/275151\/revisions"}],"predecessor-version":[{"id":275152,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/posts\/275151\/revisions\/275152"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media\/274346"}],"wp:attachment":[{"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/media?parent=275151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/categories?post=275151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canadianinquirer.net\/v1\/wp-json\/wp\/v2\/tags?post=275151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}